# Pharmacokinetics of Fixed-Dose Combination Tablet of Bemnifosbuvir and Ruzasvir

> **NCT06204679** · PHASE1 · COMPLETED · sponsor: **Atea Pharmaceuticals, Inc.** · enrollment: 42 (actual)

## Conditions studied

- Healthy Volunteer Study

## Interventions

- **DRUG:** Bemnifosbuvir (BEM)/Ruzasvir (RZR) FDC under fasting conditions
- **DRUG:** Bemnifosbuvir (BEM)/Ruzasvir (RZR) FDC under fed conditions
- **DRUG:** Bemnifosbuvir (BEM) and Ruzasvir (RZR) as reference formulation under fasting conditions

## Key facts

- **NCT ID:** NCT06204679
- **Lead sponsor:** Atea Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-12-14
- **Primary completion:** 2024-08-25
- **Final completion:** 2024-08-25
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2024-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06204679

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06204679, "Pharmacokinetics of Fixed-Dose Combination Tablet of Bemnifosbuvir and Ruzasvir". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06204679. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*